On August 27, 2024 Pillar Biosciences, Inc., the leader in Decision Medicine, reported the global launch of oncoReveal Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy (Press release, Pillar Biosciences, AUG 27, 2024, View Source [SID1234646136]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A team at New York’s Memorial Sloan Kettering Cancer Center (MSK), will be the first to utilize oncoReveal Nexus, which will be branded MSK-REACT. MSK has already received NYS DOH approval for clinical implementation of MSK-REACT, enabling a more streamlined NGS workflow to help patients get on the right therapy sooner.
oncoReveal Nexus assesses key driver genes for both hematological and solid tumor malignancies in one multiplex reaction. The assay has a fully automatable workflow that can be performed by any clinical laboratory, batching up to eighty-one patient samples in a single Illumina MiSeq sequencing run, using as little as 2.5 ng DNA per patient sample. With a sample-to-report time within 2-3 days after DNA isolation, a laboratory deploying this panel will be able to quickly assess key driver alterations prior to initiating the laboratory process for comprehensive genomic profiling (CGP), enabling more rapid time-to-treatment and laboratory cost savings.
"For the last few years, industry dialogue surrounding NGS testing has been about whether to use small panel targeted sequencing or CGP. We firmly believe that both NGS approaches are extremely complementary, have very specific benefits, and can be leveraged together to maximize laboratory efficiencies while improving overall patient outcomes," said Dan Harma, Chief Commercial Officer, Pillar Biosciences. "The launch of our oncoReveal Nexus panel at MSK to help accelerate the delivery of precision medicine really underscores our belief in this model and our company’s approach to the market."
At MSK, the newly developed and rapid panel is expected to help accelerate genomic results in parallel with the more comprehensive CGP assay MSK-IMPACT test for both solid and hematologic malignancies. In validation studies, the teams have noted 100 percent concordance between oncoReveal Nexus and MSK-IMPACT, providing a level of confidence that this approach will provide both clinical and workflow benefits.